<DOC>
	<DOCNO>NCT00865696</DOCNO>
	<brief_summary>The purpose study compare relative bioavailability 15 mg Mirtazapine Tablets Purepac Pharmaceutical Co 15 mg REMERON® Tablets Organon Inc. follow single oral dose ( 1 x 15 mg ) healthy adult volunteer fast condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Mirtazapine 15 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , single dose , two-way crossover study fast condition Official Title : A Relative Bioavailability 15 mg Mirtazapine Tablets Under Fasting Conditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Screening Demographics : All volunteer select study healthy men woman 18 year age old time dose . The weight range exceed ± 20 % height body frame per Desirable Weights Men 1983 Metropolitan Height Weight Table per Desirable Weights Women 1983 Metropolitan Height Weight Table . Screening Procedures : Each volunteer complete screening process within 30 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential ; RBC count , platelet count CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase ; HIV antibody hepatitis B surface antigen screen ; URINALYSIS : dipstick , microscopic examination dipstick positive ; . URINE DRUG SCREEN : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine . SERUM PREGNANCY SCREEN ( female volunteer ) If female : childbearing potential , practice acceptable barrier method birth control duration study judge investigator ( ) , condom , sponge , foam , jelly , diaphragm ; intrauterine device ( IUD ) , abstinence postmenopausal least I year ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) Volunteers recent history drug alcohol addiction abuse . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined medical investigator ) . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen . Volunteers demonstrate positive drug abuse screen screen study . Female volunteer demonstrate positive pregnancy screen . Female volunteer currently breastfeed . Volunteers history allergic response ( ) mirtazapine relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers clinically significant illness 4 week prior Period I dose ( determine medical investigator ) . Volunteers currently use tobacco product . Volunteers take drug know induce inhibit hepatic• drug metabolism 30 day prior Period I dose . Volunteers report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Volunteers report receive investigational drug within 30 day prior Period I dose . Volunteers report take systemic prescription medication 14 day prior Period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Mirtazapine</keyword>
	<keyword>Healthy subject</keyword>
</DOC>